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Staphylococcus aureus and Staphylococcus epidermidis are notable for their propensity to
form biofilms on implanted medical devices. Staphylococcal biofilm infections are typified
by their recalcitrance to antibiotics and ability to circumvent host immune-mediated clear-
ance, resulting in the establishment of chronic infections that are often recurrent in nature.
Indeed, the immunomodulatory lifestyle of biofilms seemingly shapes the host immune
response to ensure biofilm engraftment and persistence in an immune competent host.
Here, we provide a brief review of the mechanisms whereby S. aureus and S. epidermidis
biofilms manipulate host–pathogen interactions and discuss the concept of microenviron-
ment maintenance in infectious outcomes, as well as speculate how these findings pertain
to the challenges of staphylococcal vaccine development.
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INTRODUCTION
Staphylococcus aureus and Staphylococcus epidermidis are highly
opportunistic pathogens and a major cause of nosocomial and
community-associated infections (1–4). While both staphylo-
coccal species harbor multiple virulence factors, they are also
capable of biofilm formation, which represents a communal vir-
ulence determinant to circumvent immune-mediated clearance
and establish persistent infection (5–8). Most medical device-
associated biofilm infections are caused by S. epidermidis and
S. aureus, and both species can also establish biofilms on native
host surfaces, such as infective endocarditis and osteomyelitis (9–
11). Biofilms are heterogeneous bacterial communities encased
within a self-produced matrix composed of eDNA (12), proteins
(13), and polysaccharides (14), and their composition is often
dependent on environmental factors, such as nutrient availability
and mechanical stress (15). Biofilms represent a spatially diverse
population of cells in terms of gene expression and metabolic
activity, which is thought to arise in response to differences in
nutrient, pH, and oxygen gradients within the structure (5, 16).
Biofilm infections are recalcitrant to antibiotics (17, 18), which
often necessitates removal of the infected device or native tissue
and is associated with significant morbidity and economic impact
(10, 19, 20). Indeed, it has been estimated that approximately $1.8
billion is spent annually in the US for the treatment and clinical
management of orthopedic implant-related infections (21, 22).
Neutrophils and macrophages are the main innate immune
effectors against acute planktonic staphylococcal infections (i.e.,
abscess, sepsis) (23–29). Neutrophil antimicrobial activity is medi-
ated by defensins, cathelicidins, and lysozymes, as well as reactive
oxygen species catalyzed by NADPH oxidase (30, 31). Recently,
neutrophil and macrophage extracellular traps (NETs and METs,
respectively) have been identified as another means of antimicro-
bial action (31–34). This“beyond the grave”mechanism is typified
by an extracellular net of DNA released from dying phagocytes that
contains localized islands of lytic enzymes that kill ensnared extra-
cellular bacteria. Classically activated (M1) macrophages are key
microbicidal effectors that exert their effector functions, in part,
through the production of reactive oxygen and nitrogen species,
in addition to proinflammatory cytokines (35–38). Macrophages
also clear extracellular bacteria by phagocytosis, which is tightly
linked with proinflammatory cytokine and chemokine produc-
tion to initiate adaptive immune responses (39–41). Collectively,
these innate leukocyte responses, coupled with complement acti-
vation, usually ensure the successful clearance of planktonic
staphylococcal infections in an immune competent host.
In contrast, a very different story has emerged regarding biofilm
infections (Figure 1). Recent studies have demonstrated that
staphylococcal biofilms actively skew host immunity toward an
anti-inflammatory, pro-fibrotic response that favors bacterial per-
sistence (6, 42–44). This is typified by alternatively activated (M2)
macrophages and arginase-1 (Arg1) activity, resulting in urea and
ornithine production, which are involved in collagen formation
and tissue remodeling (35, 45, 46). Our laboratory has shown
that macrophages associated with S. aureus biofilms both in vitro
and in vivo have decreased inducible nitric oxide synthase (iNOS)
concomitant with increased Arg1 expression, as well as attenuated
cytokine and chemokine production (6, 43, 44). Similar findings
have been reported in response to S. epidermidis biofilms (42, 47–
49) and biofilms from other bacterial species (50–53), suggesting
a conserved mechanism exists to thwart host immunity to ensure
biofilm persistence (54). However, recent data suggest a protective
role of anti-inflammatory Th2/Treg cells, as opposed to proin-
flammatory Th1/Th17 signaling, during early S. aureus biofilm
development (55), highlighting the complexity of staphylococ-
cal biofilm infections and perhaps distinctions between innate
and adaptive immune mechanisms. For in-depth discussions on
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FIGURE 1 | Game of hide-and-seek between staphylococcal biofilms
and host innate immunity. (1A) Planktonic staphylococci (yellow) are
more readily phagocytosed and cleared by innate immune cells, such as
macrophages (MΦ; blue) and neutrophils (PMNs), triggering a M1
proinflammatory response. (1B) Differential gene expression between
planktonic and biofilm staphylococci provide survival benefits in harsh
environments, such as the presence of an extracellular matrix (green). In
addition, S. aureus biofilms exhibit differential gene expression in response
to macrophages or neutrophils (violet), shielding the biofilm from detection
by the former while facilitating cytotoxicity of the latter. (2A) Staphylococcal
biofilm protein secretion in vivo is relatively unknown and may represent
fertile ground for clinical intervention and/or vaccine development. (2B)
Staphylococcal biofilms are composed of a large biomass, of which some
cells are metabolically active and transform the surrounding
microenvironment by establishing various metabolic gradients. (3A)
Implanted medical devices (gray) not only provide a scaffold for bacterial
adhesion and biofilm formation that is facilitated through host protein
deposition (tan), but can also induce a persistent, anti-inflammatory
immune response that favors bacterial persistence. (3B). Tissue damage
provoked by staphylococcal nutrient procurement may further incite an
overall anti-inflammatory milieu.
host immunity to staphylococcal infections, the reader is referred
to recent reviews (7, 56–58). This Perspective is focused on
how changes in biofilm gene expression/secretion impact host
immune mechanisms and potential implications regarding novel
therapeutic strategies.
DIFFERENTIAL GENE EXPRESSION IN STAPHYLOCOCCAL
BIOFILMS: A GAME OF HIDE-AND-SEEK
Staphylococcal biofilms exhibit distinct gene expression profiles
compared to planktonic cells, demonstrating unique growth dif-
ferences between the two lifestyles (16, 59, 60). One major disparity
in staphylococcal biofilms is the induction of genes associated with
potential acid tolerance response pathways (i.e., arginine deimi-
nase and urease), reflecting anaerobic growth and the need for pH
homeostasis (5, 16). In addition, an increased demand for pyrim-
idine nucleotide biosynthesis has been associated with the biofilm
lifestyle of staphylococci (16) and other bacterial species (61, 62).
The DNA-binding regulatory protein SarA is critical for biofilm
formation and virulence factor expression in both S. aureus and
S. epidermidis. SarA acts, in part, through the accessory gene reg-
ulator agr, which encodes a quorum-sensing system responsible
for transitioning the synthesis of surface and adhesive molecules
to secreted factors and is an important regulatory switch between
planktonic and biofilm lifestyles (63–66).
In addition to unique genetic changes during biofilm growth,
we have recently reported that innate immune cells (i.e.,
macrophages and neutrophils) alter biofilm gene expression pro-
files (67). Transcriptome analysis of S. aureus biofilms following
macrophage exposure revealed a rapid down-regulation of over
550 staphylococcal genes within a 1 h period. This effect occurred
despite the fact that macrophages did not significantly invade the
biofilm or exhibit phagocytic activity. This transcriptional repres-
sion was mitigated after 24 h, which was likely explained by the
significant degree of macrophage death observed at this late inter-
val. In essence, the biofilm was no longer required to cloak itself,
since the threat of macrophage attack had dissipated. In con-
trast, although neutrophils displayed a much higher propensity
for biofilm invasion and phagocytosis, they did not significantly
alter the biofilm transcriptome over similar time periods (67).
This data supports previous reports demonstrating that biofilms
are not inherently protected from neutrophil assault (44, 68, 69).
These results suggest that staphylococcal biofilms “hide” in
response to macrophages while they elect to tackle neutrophil
challenge head on. But why does the biofilm down-regulate gene
expression in the face of a seemingly inactive macrophage chal-
lenge and barely break a transcriptional sweat when confronted
with an assault of phagocytic neutrophils? One possibility involves
the reported ability of S. aureus to survive intracellularly in neu-
trophils (70, 71). Another is that S. aureus secretes a number of
neutrophil-lytic toxins, including α-toxin (Hla) (72) and phenol-
soluble modulins (PSMs) (73–77). Interestingly, both Hla and
PSMs are under agr control, and agr expression was significantly
increased in S. aureus biofilms following neutrophil exposure (67,
74). Notably, we have found few neutrophil infiltrates in either
S. aureus catheter-associated or orthopedic implant models of
biofilm infection in vivo (7, 44). Likewise, the exogenous intro-
duction of neutrophils at the site of S. aureus biofilm infection
is not capable of limiting bacterial growth, whereas M1-activated
macrophages can significantly prevent or clear established biofilms
(44). Collectively, these findings highlight the well-adapted nature
of S. aureus biofilms to neutrophils. Although both neutrophils
and macrophages are phagocytic, macrophages are recognized as
a signaling hub during bacterial infections to coordinate evolv-
ing immune responses through cytokine and chemokine release
(78–80). While it is possible that staphylococcal biofilms are more
responsive to this secreted milieu than physical disruption via
phagocytosis, it is clear that they respond differently to chal-
lenges from distinct leukocyte populations in regards to their
transcriptional profile.
MICROENVIRONMENT MODULATION
Previous work has characterized numerous secreted virulence
factors used by staphylococci that target specific host cell pop-
ulations. S. aureus, in particular, utilizes numerous hemolysins
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(81), leukocidins (82, 83), and proteases to evade the host immune
system (84). While staphylococci certainly divert resources from
secreted to structural proteins during early biofilm growth, pro-
tein secretion is still maintained in biofilms. For example, several
reports have demonstrated that various bacterial biofilm-forming
species secrete peptides and full-length proteins (i.e., Esp) that
interfere with biofilm development of competing organisms, pre-
sumably to eliminate competition for a biofilm-friendly niche
(85–87). Additionally, studies have demonstrated evidence of host-
biofilm cross-talk involving the quorum-sensing molecules N -
Acyl homoserine lactones (AHL) (88, 89). Therefore, it is likely
that staphylococcal biofilms also secrete factors in vivo, perhaps
under quorum-sensing system regulation, in an attempt to evade
immune recognition and clearance. However, the identity of such
molecules remains to be elucidated but could represent future
attractive anti-biofilm agents.
Besides virulence factors, staphylococci also secrete mole-
cules for nutrient procurement and cell signaling. For example,
siderophores are critical for iron acquisition (90), while several
signaling molecules are important for biofilm remodeling and
dispersal, such as auto-inducing peptide (AIP) (63), nuclease
(91), and PSMs (74). While the primary roles of these mole-
cules are apparently unrelated to immune interactions, recent
evidence suggests the potential for alternative functions. For exam-
ple, nuclease, which mediates biofilm dispersal (65, 91), can also
participate in NET degradation (32). Recently, nuclease in com-
bination with adenosine synthase has been implicated in the
conversion of NETs to leukotoxic deoxyadenosine, highlighting
a clever means whereby S. aureus turns the immune response
against itself (92). In addition, S. aureus PSM expression is induced
following neutrophil phagocytosis, resulting in neutrophil lysis
and bacterial escape (74, 76, 93). This process is regulated by the
stringent response characterized by the synthesis of the intracel-
lular signaling alarmone (p)ppGpp (93). Therefore, the stringent
response provides yet another means of staphylococcal adaptation
in response to select immune pressures, something that has pre-
viously been well-established in relation to nutrient availability
and metabolism (94–99). Indeed, recent evidence has implicated
(p)ppGpp and di-cyclic NTPs as critical signals in the switch from
planktonic to biofilm growth (100).
However, secreted factors are not the only means whereby
staphylococcal biofilms could regulate the host response in an
exogenous manner. While bacteria have a plethora of environmen-
tal sensory mechanisms at their disposal, host immune cells are
also very sensitive to their surrounding environment (101–103).
Because biofilms represent a large biomass, the sum metabolic
activity of the bacteria themselves would be expected to have
an impact on pH and oxygen levels in the surrounding tissue
microenvironment. Indeed, even subtle changes in pH (101, 104)
or oxygen (102) can significantly alter the nature of the immune
response. Furthermore, novel research with fungal and bacterial
biofilms has identified a coordinated system of ROS signaling for
biofilm maturation (105). It will be interesting to see what, if
any, impact this biofilm ROS gradient has on the host immune
response and whether host-generated ROS can also act as a signal-
ing molecule within the biofilm to influence target pathways, such
as biofilm formation via quorum-sensing (105).
HIJACKING THE HOST RESPONSE
Most implanted medical devices are at risk for biofilm coloniza-
tion (4, 10, 11, 15). Upon placement, the device is conditioned by
host proteins, such as fibronectin and collagen, which can serve as
ligands for bacterial attachment via microbial surface components
recognizing adhesive matrix molecules (MSCRAMMS) (4, 9, 11,
15, 106, 107). Therefore, the wound healing responses elicited after
medical device implantation can inadvertently provide a rich envi-
ronment for bacterial colonization; however, they can also set the
stage for a very specific immune response that is incapable of medi-
ating bacterial clearance, as described below (108). Staphylococcal
biofilm-associated protein (Bap) can facilitate adherence to host
epithelial cells through the inhibition of MSCRAMM-mediated
attachment (109, 110). Following adherence, bacteria begin to pro-
liferate and accumulate by producing adherence factors and matrix
components, resulting in biofilm formation. Bacterial-derived
accumulation-associated protein (Aap) and polysaccharide inter-
cellular adhesin (PIA) are important accumulation molecules in
S. epidermidis.
Our laboratory has reported that S. aureus biofilms promote
their growth and expansion by manipulating the host immune
response (6, 43, 44, 111). Several studies demonstrated that staphy-
lococci have developed strategies to interfere with M1 macrophage
polarization either by directly inhibiting antimicrobial activity
or hindering M1 cytokine production (6, 42, 44, 48). In addi-
tion, the expression of numerous proinflammatory mediators is
significantly attenuated during S. aureus biofilm infection (6, 7,
43, 44). Since many of these molecules are also associated with
wound healing responses, their active repression by staphylococ-
cal biofilms is likely one mechanism to explain the paucity of
neutrophil and M1-activated macrophage infiltrates into biofilms
in vivo (6, 43, 44).
Besides dampening the local inflammatory environment,
numerous mechanisms likely exist to explain the chronicity of
staphylococcal biofilm infections in an immune competent host.
For example, we have demonstrated the preferential accumulation
of M2-activated macrophages in S. aureus biofilms in vivo and
in vitro typified by Arg1 concomitant with minimal iNOS expres-
sion (6, 43, 44). Increased Arg1 activity during staphylococcal
infection can regulate T cell proliferation and effector functions
via arginine depletion from the environment, resulting in defective
TCR signaling from inhibiting CD3ζ expression, cell cycle, and
cytokine production (112–116). Indeed, our laboratory has found
few T cell infiltrates associated with S. aureus biofilm infections,
whereas another group reported Th2/Treg involvement in biofilm
clearance (7, 55). The reasons for these discrepancies are not clear
but may arise from differences in experimental models and/or
S. aureus strains tested. Impaired adaptive immunity or mem-
ory responses could compromise the success of vaccine strategies
against staphylococcal biofilms.
FUTURE DIRECTIONS
As ongoing staphylococcal biofilm research elucidates mecha-
nisms contributing to the persistence and virulence of these
infections, it is becoming clear that novel strategies are needed
to combat the complex biofilm lifestyle. The inherent abil-
ity of S. aureus to circumvent immune-mediated clearance has
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complicated staphylococcal vaccine development. Indeed, pre-
vious studies have shown that S. aureus infection alone is not
sufficient to induce protective immunity (117). Moreover, recent
vaccine development efforts have stalled in clinical trials, likely
due to the organism’s immunomodulatory capabilities coupled
with the differential expression of targeted antigens in vivo (118–
120). Another challenge is to develop a vaccine efficacious against
both planktonic and biofilm infections that provides protection
across a wide range of S. aureus clonal complex groups (121).
Recent staphylococcal vaccine efforts have utilized new
approaches to increase efficacy. Vaccination with attenuated S.
aureus strains (122) has led to the discovery of protective antigens
with vaccine potential in a process termed “genetic vaccinology”
(123, 124). In addition, multivalent vaccines targeting multiple
secreted and cell surface-associated virulence factors from both
planktonic (125), and biofilm (126, 127) modes of growth have
been employed with some success in vivo (121, 128). Further-
more, the use of Toll-like receptor agonists as adjuvants and novel
DNA vaccines are currently under investigation (129, 130). While
the efforts of our laboratory and others have implicated a sub-
set of putative factors responsible for the immunosuppressive
and chronic nature of staphylococcal biofilms, significant obsta-
cles remain for developing a successful vaccine. In our opinion,
future anti-staphylococcal therapeutics for the biofilm lifestyle
will likely require a combinatorial approach of bacteriocidal and
immunostimulatory treatments.
In this context, a successful staphylococcal vaccine may be facil-
itated by a more comprehensive understanding of the staphylococ-
cal biofilm transcriptome and secretome, particularly in response
to relevant host phagocytes, which will be an important next
step toward replicating complex in vivo interactions. Additional
insights into staphylococcal biofilm metabolism, in particular, how
the biofilm metabolome changes once immune cells are encoun-
tered, may be beneficial as it could facilitate the identification of
virulence determinants for vaccine development. A recent analogy
is the use of metabolic stimuli to induce aminoglycoside suscepti-
bility in otherwise recalcitrant S. aureus cell populations, such as
biofilms (131). Also, characterizing how the natural wound healing
response promotes bacterial colonization could provide invaluable
information on key immune cell populations for vaccine target-
ing. A better understanding of how biofilms manipulate the host
immune response should provide valuable insights to direct the
continued evolution of staphylococcal vaccines. Until, we better
define how staphylococci circumvent host immunity, they will
likely continue to have the upper hand.
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